Concentration-effect studies with topiramate on selected enzymes and intermediates of the GABA shunt

Epilepsia

Volumn 41, Issue SUPPL. 1, 2000, Pages 30-34

  Sills, Graeme J ^a   Leach, John P ^a   Kilpatrick, W Stewart ^a   Fraser, Caroline M ^a   Thompson, George G ^a   Brodie, Martin J ^a  

^a WESTERN INFIRMARY   (United Kingdom)

Author keywords

Antiepileptic drugs; Epilepsy; GABA; Glutamate; Topiramate

Indexed keywords

4 AMINOBUTYRATE AMINOTRANSFERASE; 4 AMINOBUTYRIC ACID; 4 AMINOBUTYRIC ACID RECEPTOR; CARBONATE DEHYDRATASE; GLUTAMATE DECARBOXYLASE; GLUTAMATE RECEPTOR; GLUTAMIC ACID; GLUTAMINE; SODIUM; SODIUM CHANNEL; TOPIRAMATE;

ANIMAL TISSUE; ARTICLE; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; EPILEPSY; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL;

4-AMINOBUTYRATE TRANSAMINASE; ANIMALS; ANTICONVULSANTS; BRAIN; BRAIN CHEMISTRY; DISEASE MODELS, ANIMAL; DOSE-RESPONSE RELATIONSHIP, DRUG; EPILEPSY; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; GLUTAMATE DECARBOXYLASE; GLUTAMIC ACID; GLUTAMINE; MALE; MICE; MICE, INBRED ICR; NEURONS; RANDOM ALLOCATION; RECEPTORS, GABA-A; RECEPTORS, GLUTAMATE;

EID: 0034087350     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.2000.tb02168.x     Document Type: Article

References (24)

1. Dichter MA, Brodie MJ. New antiepileptic drugs. N Engl J Med 1996;334:1583-90.
2. Langtry HD, Gillis JC, Davis R. Topiramate: a review of its pharmacodynamic and pharmacokinetic properties and clinical efficacy in the management of epilepsy. Drugs 1997;54:752-73.
3. Shank RP, Gardocki JF, Vaught JL, et al. Topiramate: preclinical evaluation of a structurally novel anticonvulsant. Epilepsia 1994; 35:450-60.
4. Wauquier A, Zhou S. Topiramate: a potent anticonvulsant in the amygdala-kindled rat. Epilepsy Res 1996;24:73-7.
5. White US, Woodhead JH, Wolf HH. Effect of topiramate (TPM) on pentylenetetrazol (PTZ) seizure threshold. Epilepsia 1996;37 (suppl 5):26.
6. Edmonds HL, Jiang JD, Zhang PY, Shank RP. Anticonvulsant activity of topiramate and phenytoin in a rat model of ischaemia-induced epilepsy. Life Sci 1996;59:PL127-31.
7. Nakamura J, Tamura S, Kanda T, et al. Inhibition by topiramate of seizures in spontaneously epileptic rats and DBA/2 mice. Eur J Pharmacol 1994;254:83-9.
8. Coulter DA, Sombati S, DeLorenzo RJ. Selective effects of topiramate on sustained repetitive firing and spontaneous bursting in cultured hippocampal neurons. Epilepsia 1993;34(suppl 2):123.
9. Kawasaki H, Lopantsev V, Zona C, Avoli M. Topiramate depresses intrinsic bursts in the rat subiculum in vitro. Epilepsia 1996;37(suppl 5):26.
10. Zona C, Ciotti MT, Avoli M. Topiramate attenuates voltage-gated sodium currents in rat cerebellar granule cells. Neurosci Lett 1997; 231:123-6.
11. Coulter DA, Sombati S, DeLorenzo RJ. Topiramate effects on excitatory amino acid-mediated responses in cultured hippocampal neurons: selective blockade of kainate currents. Epilepsia 1995;36 (suppl 3):S40.
12. White HS, Brown SD, Woodhead JH, Skeen GA, Wolf HH. Topiramate enhances GABA-mediated chloride flux and GABA-evoked chloride currents in murine brain neurons and increases seizure threshold. Epilepsy Res 1997;28:167-79.
13. Kuzniecky R, Hetherington H, Ho S, et al. Topiramate increases cerebral GABA in healthy humans. Neurology 1998;51:627-9.
14. Petroff OAC, Hyder F, Mattson RH. Topiramate increases brain GABA, homocarnosine, and pyrrolidinone in patients with epilepsy. Neurology 1999;52:473-8.
15. Sills GJ, Leach JP, Fraser CM, Forrest G, Patsalos PN, Brodie MJ. Neurochemical studies with the novel anticonvulsant levetiracetam in mouse brain. Eur J Pharmacol 1997;325:35-40.
16. Faught E, Wilder BJ, Ramsay RE, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 200-, 400-, and 600-mg daily dosages. Neurology 1996;46:1684-90.
17. Privitera M, Fincham R, Penry J, et al. Topiramate placebo-controlled dose-ranging trial in refractory partial epilepsy using 600-, 800-, and 1000-mg daily dosages. Neurology 1996;46:1678-83.
18. Meldrum BS. Epilepsy and γ-aminobutyric acid-mediated inhibition. Int Rev Neurobiol 1975;17:1-36.
19. Schousboe A. Transport and metabolism of glutamate and GABA in neurons and glial cells. Int Rev Neurobiol 1981;22:1-45.
20. Petroff OAC, Rothman DL, Behar KL, Collins TL, Mattson RH. Human brain GABA levels rise rapidly after initiation of vigabatrin therapy. Neurology 1996;47:1567-71.
21. Petroff OAC, Rothman DL, Behar KL, Lamoureux D, Mattson RH. The effect of gabapentin on brain gamma-aminobutyric acid in patients with epilepsy. Ann Neurol 1996;39:95-9.
22. Jung MJ, Lippert B, Metcalf BW, Böhlen P, Schechter PJ. γ-Vinyl GABA (4-amino-hex-5-enoic acid), a new selective irreversible inhibitor of GABA-T: effects on brain GABA metabolism in mice. J Neurochem 1977;29:797-802.
23. Taylor CP, Gee NS, Su T-Z, et al. A summary of mechanistic hypotheses of gabapentin pharmacology. Epilepsy Res 1998;29: 233-49.
24. Leach JP, Sills GJ, Butler E, Forrest G, Thompson GG, Brodie MJ. Neurochemical actions of vigabatrin and tiagabine alone and in combination in mouse cortex. Gen Pharmacol 1997;28:715-9.